Apotex supports launch of home-based cancer care with $1.5M donation
Oct 8, 2025Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
Cancer Care at Home combines remote monitoring, urgent oncology support and hospital-to-home services to create a seamless care pathway. The program aims to reduce emergency visits, ease transitions after hospital stays and provide guidance between appointments.
"Apotex is excited to support the launch of this innovative program that puts patients at the center and allows them to receive care where they are most comfortable," says Allan Oberman, President and CEO of Apotex. "Our team is committed to supporting those on their journey of health and enabling care at home. Patients and their families will truly benefit from this program and we are honoured to partner with Sunnybrook to make it possible."
This initiative reflects Apotex's commitment to expanding access to patient-centred care and supporting healthier communities. It also reinforces our role as a trusted partner in advancing innovative healthcare solutions.
Learn more about Cancer Care at Home and read the full press release here.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Jul 17, 2026
Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
Toronto, ON, July 16, 2026. Apotex Health Corp ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.
-
Jul 8, 2026
Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection
Toronto, ON, July 8, 2026 – Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.